Stock Region Penny Picks
Movers, Shakers, and a Sonic Weapon?
Movers, Shakers, and a Sonic Weapon?
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: Hold on tight! This newsletter is for informational and entertainment purposes only. The content here is based on the team’s personal opinions, research, and the occasional gut feeling. It is NOT financial advice. Investing in stocks, especially the ones we talk about, carries significant risk. Please do your own research and consult with a licensed financial advisor before making any investment decisions. We are not a financial advisor.
What a day in the markets today. We saw a flurry of press releases, and some of these moves have the team’s full attention. Let’s break down what’s on the team’s radar for today, January 21, 2026.
The Morning Movers
Here are the tickers that had the team chugging coffee a little faster this morning.
$CRVS (Corvus Pharmaceuticals): They announced positive data from a clinical trial for their atopic dermatitis treatment, Soquelitinib. Biotech is always a wild ride, but positive trial data is the fuel these rockets run on. This is a big step for them, and the we’ll be watching to see if the market rewards this milestone. Keep an eye on the volume here.
$TWG (TWG): This one is interesting. They’re acquiring a wine authentication and trading business. It feels a bit out of left field, but think about the luxury goods market. Authenticity is everything. If they can successfully integrate this tech, it could be a unique niche. Definitely an oddball, but oddballs can sometimes be the biggest winners.
$SDST (Sandstorm): They received an air quality permit for their lithium refinery in Oklahoma. This might sound boring, but it’s a huge hurdle to clear. With the EV market’s insatiable hunger for lithium, any company making progress in domestic production is worth a look. This is a long-term play, but a critical piece of the puzzle just fell into place for them.
$DRMA (Dermata): An Australian patent for an acne treatment. Patents are the name of the game in pharma. It protects their intellectual property and carves out their piece of the market. It’s a good sign of progress, and while Australia is just one market, it builds the global case for their product.
$FRSX (Foresight): A collaboration with SoftBank in Japan to test their collision prevention tech. Anytime you see a name like SoftBank pop up, you have to pay attention. This is a significant validation for Foresight’s technology. It’s still in the validation phase, but a partnership like this can open massive doors.
$IBG (Innovation Beverage Group): They’re expanding their energy drink line and proposing a merger. The energy drink market is crowded, but a merger could provide the scale and resources they need to compete. We’re waiting for more details on this one, but it’s on the watchlist.
$ALBT (Avalon GloboCare): FDA registration renewal for their KetoAir device and a planned launch using a generative AI video platform. This is a mouthful, but it hits all the right buzzwords: health tech, AI, and SaaS. It feels very “2026.” We’re curious to see if the product and the marketing strategy can actually deliver.
The Sound of War? ($GNSS)
Now for the one that really blew our mind. Genasys Inc. ($GNSS).
This company makes Long Range Acoustic Devices (LRADs). The official line is they’re for hailing and mass notification. But let’s be real. When used in “Alert Mode,” this thing is a non-lethal weapon. It blasts a focused beam of sound so intense (up to 160 decibels) that it can cause severe pain, disorientation, vertigo, and permanent hearing damage. It doesn’t knock you out; it makes you wish you were.
Just last week, US forces captured Venezuelan leader Maduro in “Operation Absolute Resolve.” Now, reports are trickling out from Venezuelan guards describing symptoms like intense nausea, vertigo, and crippling migraines. Sound familiar?
The timeline here is what got our attention
September 2025: Genasys wins a contract to mount these LRADs on Army vehicle turrets.
January 2026: A raid in Venezuela where the described symptoms perfectly match the effects of an LRAD.
Coincidence? Highly doubt it. It looks like their tech was just battle-tested and proved devastatingly effective in a high-profile special operation.
From an investment standpoint, this is massive. If the U.S. military is actively and successfully deploying your hardware, what do you think that does for future sales, both domestic and international? This is a game-changer for Genasys. The world just saw a real-world demo of their product’s “other” capabilities. We are definitely keeping $GNSS at the very top of the team’s list today.
That’s all for now. It’s going to be another exciting day. Keep your heads on a swivel, do your own homework, and may your trades be green.
Talk soon,
The Stock Region Team
Final Disclaimer: Seriously, this is not financial advice. All stock tickers mentioned are for discussion and entertainment. the team’s may or may not hold positions in any of the stocks discussed. The stock market is volatile. Invest responsibly.